Cerclage for prevention of preterm birth in women with a short cervix: a multicenter randomized trial
Source: View publication →
In women with a history of spontaneous preterm birth and a sonographically short mid-trimester cervix, prophylactic cerclage reduced the risk of previable birth and perinatal mortality, though it did not significantly reduce the overall rate of preterm birth before 35 weeks except in the subgroup with the most severe cervical shortening (<15 mm).
Key Findings
Study Design
Study Limitations
Clinical Significance
These findings support the use of ultrasound-indicated cerclage specifically in high-risk women (those with a prior spontaneous preterm birth) who are identified with a shortened mid-trimester cervix, particularly when the cervical length is severely reduced (<15 mm).
Historical Context
For decades, the role of cerclage for cervical insufficiency was controversial due to inconsistent results from studies based solely on obstetric history. The introduction of transvaginal ultrasonography in the second trimester allowed for more precise identification of cervical shortening, leading to trials investigating whether targeted mechanical support could improve outcomes in at-risk cohorts.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for placing a cervical cerclage in a patient with a shortened cervix, and how does this mechanism differ from the use of vaginal progesterone?
Key Response
Cervical cerclage provides physical reinforcement to a structurally weakened cervix and helps maintain the cervical mucus plug, which acts as a barrier to ascending infection. In contrast, vaginal progesterone works biochemically to maintain uterine quiescence, inhibit cervical ripening, and modulate the inflammatory response at the maternal-fetal interface.
A patient with a history of spontaneous preterm birth (sPTB) at 26 weeks is found to have a cervical length of 21 mm at her 19-week anatomy scan. Based on the findings of this multicenter trial, how should you counsel her regarding the efficacy of cerclage in preventing birth before 35 weeks versus preventing previable birth?
Key Response
The study demonstrated that while cerclage did not significantly reduce the overall rate of preterm birth before 35 weeks in the total cohort (CL <25 mm), it did significantly reduce the risk of previable birth (<24 weeks) and perinatal mortality. Therefore, the counseling should emphasize the reduction in the most severe adverse outcomes even if the total 'preterm' rate remains similar.
The study noted a significant treatment effect for the subgroup with a cervical length <15 mm. How does this finding influence the 'expectant management vs. immediate cerclage' debate for patients with prior sPTB and a cervix measuring between 15-25 mm?
Key Response
This finding suggests a 'dose-response' relationship where the more severe the cervical shortening, the more beneficial the mechanical support of a cerclage. For those in the 15-25 mm range, the benefit is less clear for late-preterm prevention, but because of the reduction in perinatal mortality seen in the overall 'high-risk history' group, most subspecialists still recommend cerclage at the <25 mm threshold rather than waiting for further shortening to <15 mm.
Given the reduction in perinatal mortality and previable birth despite a non-significant primary outcome (PTB <35 weeks), how should this trial's results change our definition of 'success' in prematurity prevention trials?
Key Response
This trial highlights the clinical discordance between 'gestational age at delivery' and 'neonatal survival.' It suggests that in high-risk populations, preventing extreme prematurity (previability) is a more meaningful clinical target than shifting delivery from 34 to 36 weeks, arguing for the use of composite neonatal morbidity/mortality scores as primary endpoints in future cerclage research.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the statistical implications of the subgroup analysis performed for cervical length <15 mm. How does the lack of a pre-planned interaction test limit the generalizability of the conclusion that cerclage is only effective below this threshold?
Key Response
Post-hoc or non-stratified subgroup analyses are prone to Type I errors and are often underpowered. Without a formal test for interaction between cervical length and the treatment effect, one cannot definitively conclude that the treatment works differently across the 0-24 mm spectrum; it may simply be that the 'effect size' was too small to detect in the 15-24 mm group given the lower baseline risk.
As a reviewer, what concerns would you raise regarding the potential for 'provider bias' in a non-blinded surgical trial like this, particularly concerning the use of co-interventions like bed rest or progesterone?
Key Response
Since surgeons and patients were not blinded, providers might have managed the 'no-cerclage' group more conservatively (e.g., increased bed rest) or the 'cerclage' group more aggressively with other treatments. If co-interventions were not strictly standardized and reported, they could confound the relationship between the cerclage itself and the reduction in perinatal mortality.
ACOG Practice Bulletin 142 and SMFM guidelines recommend cerclage for women with a prior sPTB and a cervical length <25 mm. Does the lack of significant reduction in PTB <35 weeks in this specific trial warrant a move toward a more restrictive threshold, such as <15 mm?
Key Response
Current guidelines incorporate this study into larger meta-analyses (such as those by Berghella et al.) which collectively show a significant reduction in PTB <35 weeks for the <25 mm threshold. Because this trial showed a significant benefit in perinatal mortality for the entire <25 mm group, current guidelines maintain the more inclusive threshold to capture the patients at risk for the most catastrophic outcomes, despite the 'negative' primary result of this individual trial.
Clinical Landscape
Noteworthy Related Trials
Berghella et al.
Tested
Cervical cerclage
Population
Women with short cervix identified by ultrasound (meta-analysis of randomized trials)
Comparator
Expectant management
Endpoint
Preterm birth < 35 weeks
Hassan et al.
Tested
Vaginal progesterone (200mg daily)
Population
Women with a cervical length of 10-20mm
Comparator
Placebo
Endpoint
Preterm birth < 33 weeks
Toftager et al.
Tested
Cervical cerclage
Population
Women with singleton pregnancies and short cervix identified by ultrasound
Comparator
Expectant management
Endpoint
Preterm birth before 34 weeks of gestation
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis